sorafenib has been researched along with (1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies ((1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine) | Trials ((1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine) | Recent Studies (post-2010) ((1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 9 | 0 | 8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, SH; Cheon, JH; Cho, KJ; Joo, DJ; Kim, BK; Kim, DY; Kim, MD; Kim, SU; Lee, HW; Park, HJ; Park, JY; Seo, SH; Yook, JI | 1 |
1 other study(ies) available for sorafenib and (1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine
| Article | Year |
|---|---|
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma.
Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Glycogen Synthase Kinase 3 beta; Humans; Liver Neoplasms; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sorafenib | 2023 |